SCHEMBL25850110

SCHEMBL25850110

CCCCCC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.73
▸ NOD1 Q9Y239 9/20 0.54
▸ CCKAR P32238 3/20 0.46
▸ CCKBR P32239 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13624940 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL15359946 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL12686714 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL15359922 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL15359921 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL13494664 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL15360227 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL22648039 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL22030215 0.94 GLP1R (0.82) GLP1RNOD1
SCHEMBL16192888 0.94 GLP1R (0.82) GLP1RNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840560-B2 Prodrugs and uses thereof NOVO NORDISK A/S (DK) 2023-12-12 — — US disclosed
US-20230227521-A1 PRODRUGS AND USES THEREOF NOVO NORDISK A/S (DK) 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840560-B2 Prodrugs and uses thereof GIPR, GLP1R, GRPR GLP1R 2/4885NOD1 687/4885CCKAR 21/4885
US-20230227521-A1 PRODRUGS AND USES THEREOF GIPR, GLP1R, GRPR GLP1R 2/4885NOD1 687/4885CCKAR 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback